Clinical Trial Update: PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) [Phase 2]

View source ↗

Summary

Phase 2 trial update for PNT2258 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• PNT2258

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Lymphoma, Diffuse Large B-Cell | Phase 2 | Status: COMPLETED | Results posted: 2020-04-22